Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus F Neurath

Showing results (61-70 of 775) with videos related to

Pageof 78
Sort By:
Immunotargets and Therapy|December 4, 2020
All are Equal, Some are More Equal: Targeting IL 12 and 23 in IBD - A Clinical PerspectiveAndré Jefremow, Markus F Neurath
Nature Reviews. Gastroenterology & Hepatology|October 17, 2012
Ulcerative colitis: UCCIS--a reproducible tool to assess mucosal healingHelmut Neumann, Markus F Neurath
Cellular and Molecular Life Sciences : CMLS|May 17, 2014
Colitis-associated neoplasia: molecular basis and clinical translationSebastian Foersch, Markus F Neurath
Gut|August 28, 2023
Different levels of healing in inflammatory bowel diseases: mucosal, histological, transmural, barrier and complete healingMarkus F Neurath, Michael Vieth
The Lancet. Gastroenterology & Hepatology|January 10, 2025
No easy way out: blocking lymphocyte egress by the S1P1 receptor 1 modulator tamuzimod in ulcerative colitisRaja Atreya, Markus F Neurath
Expert Review of Clinical Immunology|November 13, 2015
How will new and future therapies change our treatment of IBD?Sebastian Zundler, Markus F Neurath
Vaccines|March 4, 2016
Integrating Immunologic Signaling Networks: The JAK/STAT Pathway in Colitis and Colitis-Associated CancerSebastian Zundler, Markus F Neurath
Gastroenterology|June 6, 2022
Rear Window-What Can the Gut Tell Us About Long-COVID?Moritz Leppkes, Markus F Neurath
Visceral Medicine|June 15, 2017
Current and Future Targets for Mucosal Healing in Inflammatory Bowel DiseaseRaja Atreya, Markus F Neurath
Expert Opinion on Therapeutic Targets|December 11, 2002
T-bet as a possible therapeutic target in autoimmune diseaseBenno Weigmann, Markus F Neurath
Pageof 78

Showing results (61-70 of 775) with videos related to

Sort By:
Pageof 78
Immunotargets and Therapy|December 4, 2020
All are Equal, Some are More Equal: Targeting IL 12 and 23 in IBD - A Clinical PerspectiveAndré Jefremow, Markus F Neurath
Nature Reviews. Gastroenterology & Hepatology|October 17, 2012
Ulcerative colitis: UCCIS--a reproducible tool to assess mucosal healingHelmut Neumann, Markus F Neurath
Cellular and Molecular Life Sciences : CMLS|May 17, 2014
Colitis-associated neoplasia: molecular basis and clinical translationSebastian Foersch, Markus F Neurath
Gut|August 28, 2023
Different levels of healing in inflammatory bowel diseases: mucosal, histological, transmural, barrier and complete healingMarkus F Neurath, Michael Vieth
The Lancet. Gastroenterology & Hepatology|January 10, 2025
No easy way out: blocking lymphocyte egress by the S1P1 receptor 1 modulator tamuzimod in ulcerative colitisRaja Atreya, Markus F Neurath
Expert Review of Clinical Immunology|November 13, 2015
How will new and future therapies change our treatment of IBD?Sebastian Zundler, Markus F Neurath
Vaccines|March 4, 2016
Integrating Immunologic Signaling Networks: The JAK/STAT Pathway in Colitis and Colitis-Associated CancerSebastian Zundler, Markus F Neurath
Gastroenterology|June 6, 2022
Rear Window-What Can the Gut Tell Us About Long-COVID?Moritz Leppkes, Markus F Neurath
Visceral Medicine|June 15, 2017
Current and Future Targets for Mucosal Healing in Inflammatory Bowel DiseaseRaja Atreya, Markus F Neurath
Expert Opinion on Therapeutic Targets|December 11, 2002
T-bet as a possible therapeutic target in autoimmune diseaseBenno Weigmann, Markus F Neurath
Pageof 78